Tarrytown, New York -- August 11, 2015 -- Good Publication Practice 3 (GPP3), a key guidance document for the publication of company-sponsored medical research, has been published online today by the Annals of Internal Medicine (AIM). “The publication of GPP3 in AIM provides important acknowledgement of the commitment individuals and industry must make in maintaining ethical and transparent publication practices,” said Wendy P. Battisti, PhD, lead author and Chair of the GPP3 Steering Committee.
GPP3 is an update of the original Good Publication Practice (GPP) guidelines, which were originally published in 2003 and updated for the first time in 2009. The ISMPP GPP3 Steering Committee has now brought the 2009 version of the guidelines for good publication practice (GPP2) up to date to increase the focus on integrity and transparency in industry-sponsored publication planning and development in today’s environment. The Steering Committee consisted of 18 globally diverse individuals representing industry (pharma and device) and medical communications companies including, freelance writers, journal editors and publishers. The Steering Committee was further supported in this effort by the contribution of 94 reviewers obtained through an extensive global review process.
New areas addressed in GPP3 include guidance on the most recent ICMJE authorship criteria (2013), common issues regarding authorship, improved clarity on author payment and reimbursement, clarification as to what constitutes ghost writing or guest authorship, the role and benefit of professional medical writers, and guidance for appropriate data sharing.
According to Terry Peña, PhD, GPP3 co-author and Chair of ISMPP’s Board of Trustees, “GPP3 has been developed to benefit all stakeholders in medical publications, in addition to working in concert with other guidelines, such as the International Committee of Medical Journal Editors authorship guidelines and Consolidated Standards of Reporting Trials”. The publication also includes a guiding principles section and a quick reference table addressing guidance on authorship criteria and related issues.
The hope of the GPP3 steering committee and authors is that this publication will help those developing medical publications better interpret and apply the guidelines, while promoting transparency and integrity in biomedical writing. “We are excited about the publication in AIM, and with ISMPP’s assistance, look forward to broader awareness and adoption of these best publication practices”, said Dr. Battisti.
For more information on GPP3, and to view the publication, go to http://www.ismpp.org/gpp3.
About the International Society for Medical Publication Professionals: ISMPP is an independent non-profit professional association with members from the pharmaceutical, medical device, and biotechnology industries; publication planning and medical communication companies; academia; and medical journal staff, including editors and publishers. Its goals are to support the educational needs of publication professionals and to develop best practices that ensure the rigorous maintenance of all ethical standards for reporting results of medical research. Additional information about ISMPP is available by contacting the organization’s President, Al Weigel (phone: 520-820-08594; e-mail: firstname.lastname@example.org) or online at http://www.ismpp.org.